Dr Elaine Sullivan
Dr Elaine Sullivan joined IP Group’s Board in 2015. She has over 25 years’ international experience in the pharmaceutical industry and was a member of senior management teams in R&D at Eli Lilly and AstraZeneca. From 2011 to 2015, Dr Sullivan was Vice President Global External Research & Development in the US for Eli Lilly, where she led a global workforce delivering access to business critical external innovation. Prior to this, she spent over 15 years at AstraZeneca where she held a number of roles including Vice President, Science & Technology, in which she identified and established novel drug-hunting approaches from target to delivery of proof of concept, and Vice President, R&D New Opportunities, establishing and leading the first virtual Therapy Area in AstraZeneca. In 2015, she founded a specialist oncology company, Carrick Therapeutics, and holds the position of Chief Executive. She is also a Member of the Supervisory Board of Evotec AG, a drug discovery solutions company.